A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The overall objective is to increase the adherence to national guidelines for patients with established CVD and/or Type 2 diabetes by means of repeated post-graduate educational meetings and regular evaluation of the optimisation initiatives, demonstrated by improvement of goal attainment in general practice.
Condition or disease
Heart DiseasesDiabetes Mellitus, Type 2
Behavioral: Patient adherence to national educational guidelines.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Primary care clinic patients
Subjects had to meet all of the inclusion criteria to be eligible for enrollment into the study. The following subjects qualify for inclusion in the study:
Subjects for whom measurement of total cholesterol, low density lipoprotein (LDL) cholesterol, blood pressure (BP) and glycosylated hemoglobin (HbA1c) was planned independently of this observational study and for whom baseline values were or became available.
Subjects with known CVD diagnosed > or = 6 months before inclusion
Previous myocardial infarction
Ischemic heart disease (stable and unstable angina pectoris)
Peripheral arterial disease
Subjects with T2D diagnosed > or = 6 months before inclusion
At least 50% of the subjects had to have CVD as the primary diagnosis. It was allowed for a secondary diagnosis to be <6 months before inclusion.
Subjects presenting with any of the following were not to be included in the study:
Life expectancy of < or = 2 years
Unable/unwilling to understand/follow instructions
Taking part in a clinical study involving an investigational drug
Followed by a specialist for their CVD and/or T2D at the time of inclusion in the study